LNF1802

LNF1802 is an investigational, orally bioavailable small molecule inhibitor of the fibroblast growth factor receptor (FGFR) family, specifically targeting FGFR1, FGFR2, and FGFR3. Developed by Shandong New Era Pharmaceutical (a subsidiary of Lunan Pharmaceutical Group), LNF1802 is designed to treat advanced solid tumors characterized by FGFR alterations, such as gene amplifications, mutations, or fusions. By selectively binding to the ATP-binding site of these receptors, the drug inhibits their tyrosine kinase activity, thereby blocking downstream signaling pathways including MAPK/ERK and PI3K/AKT that drive tumor cell proliferation, survival, and angiogenesis. It is currently undergoing Phase 1 clinical evaluation to determine its safety, tolerability, and preliminary efficacy in patients with refractory advanced malignancies.